Frankincense shows genuine promise against neuropathy in laboratory and animal research, but no human clinical trial has yet tested it specifically for neuropathic pain. The active compounds in frankincense resin, particularly a group called boswellic acids, reduce nerve inflammation, ease pain sensitivity, and even promote nerve repair in rodent models. That is an encouraging start, and it explains why frankincense appears so often in alternative-medicine recommendations for nerve pain. But “promising in mice” and “proven in people” are very different things, and anyone considering frankincense for neuropathy deserves a clear look at what the science actually supports right now.
What Animal Studies Show About Neuropathic Pain
The most direct evidence comes from studies using a combination of frankincense and myrrh in mice with experimentally induced nerve damage. In one well-cited study, mice receiving the frankincense-myrrh treatment showed significant relief from both thermal and mechanical hypersensitivity, two hallmarks of neuropathic pain. The researchers traced the effect to reduced neuroinflammation in the spinal cord, specifically the suppression of a signaling cascade that amplifies pain signals from damaged nerves.1PubMed. Frankincense-Myrrh treatment alleviates neuropathic pain via the inhibition of neuroglia activation mediated by the TLR4/MyD88 pathway and TRPV1 signaling An earlier study using the same herbal pairing in a different mouse model of nerve injury confirmed pain relief and identified a receptor on nerve cells called TRPV1 as a key target.2PubMed Central. A Combined Water Extract of Frankincense and Myrrh Alleviates Neuropathic Pain in Mice via Modulation of TRPV1
These are real, measurable effects, not folklore. The mice moved more normally, reacted less to painful stimuli, and showed less inflammation in their spinal tissue. The caveat is that both studies used the combination of frankincense and myrrh, not frankincense alone, and both were conducted in mice whose nerve injuries were surgically created. Whether those results translate to the slow, metabolic nerve damage behind diabetic neuropathy or the diffuse nerve problems caused by chemotherapy is unknown.
How Frankincense Compounds Affect Nerve Inflammation
The active ingredients in frankincense resin are boswellic acids, a family of compounds found in the gum resin of Boswellia trees. Among them, AKBA (acetyl-keto-boswellic acid) is considered the most potent.3PubMed Central. Frankincense (rǔ xiāng; Boswellia species): from the selection of traditional applications to the novel phytotherapy for the prevention and treatment of serious diseases Boswellic acids block an enzyme involved in producing inflammatory molecules called leukotrienes, and they also protect neurons from oxidative damage by calming the activity of immune cells in the brain and spinal cord.4Phytomedicine Plus. Frankincense unveiled: Phytochemistry, bioactivity, and future directions
In the context of neuropathy, this matters because chronic nerve inflammation is both a cause and a consequence of nerve damage. When a nerve is injured, immune cells in the spinal cord ramp up inflammatory signaling, which can amplify pain signals even after the original injury has stabilized. Boswellic acids appear to interrupt this cycle at multiple points, dampening the inflammatory cascade and reducing the expression of proteins that keep pain signaling elevated.5PubMed. Mechanistic role of boswellic acids in Alzheimer’s disease: Emphasis on anti-inflammatory properties That multi-target action is part of what makes the compounds interesting to researchers. Many conventional nerve-pain drugs hit only one receptor or pathway; boswellic acids seem to affect several at once.
Evidence for Nerve Repair and Regeneration
Beyond pain relief, some of the most intriguing findings involve frankincense’s ability to support actual nerve regrowth, at least in rats with crushed sciatic nerves. In one study, rats given frankincense extract at higher doses showed significantly improved neurological function by two weeks after injury compared with untreated controls, and the improvement continued through four weeks. The extract also increased expression of GAP-43, a protein associated with growing nerve fibers, and promoted the proliferation of Schwann cells, the cells that form the protective sheath around peripheral nerves.6PubMed Central. Effect of Frankincense Extract on Nerve Recovery in the Rat Sciatic Nerve Damage Model
Separate studies focusing on AKBA specifically confirmed this Schwann cell effect. When AKBA was given to rats with sciatic nerve injuries, the compound boosted a signaling pathway that drives Schwann cell growth and myelination, the process by which nerve fibers get re-insulated so they can conduct signals properly.7PubMed. Acetyl-11-keto-β-boswellic acid regulates the repair of rat sciatic nerve injury by promoting the proliferation of Schwann cells In lab-dish experiments, the optimal concentration for Schwann cell growth was identified, and blocking the signaling pathway partially reversed the effect, confirming that the pathway was genuinely involved.8PubMed Central. Acetyl-11-keto-β-boswellic acid extracted from Boswellia serrata promotes Schwann cell proliferation and sciatic nerve function recovery
Nerve regeneration is the holy grail for neuropathy treatment. Most existing drugs manage pain but do nothing to repair the underlying nerve damage. If frankincense compounds genuinely support Schwann cell activity and remyelination in humans, that would be a different category of treatment entirely. But the leap from a surgically crushed nerve in a young rat to the slowly degenerating nerves in a sixty-year-old with diabetes is enormous, and no human study has attempted to bridge it yet.
Oxidative Stress and the Diabetes Connection
Diabetic neuropathy is the most common form of neuropathy worldwide, and oxidative stress plays a major role in how high blood sugar damages nerves over time. Several animal studies have tested whether frankincense can counteract this oxidative damage. In diabetic rats given frankincense supplements for four weeks, key antioxidant enzymes that had collapsed under diabetic stress were partially restored, and a marker of oxidative damage called MDA dropped substantially.9International Journal of Pharmacology. Protective Effects of Frankincense Supplementation Against Oxidative Stress and Inflammatory Imbalance in Diabetic Rats The same study found reductions in several inflammatory markers, reinforcing the idea that frankincense hits both oxidative and inflammatory aspects of diabetic tissue damage simultaneously.
A similar pattern appeared in a Parkinson’s disease mouse model, where frankincense treatment restored antioxidant enzyme activity and reduced oxidative damage markers in a dose-dependent fashion.10PubMed Central. Frankincense improves motor symptoms and attenuates the progression of Paraquat (PQ)-induced Parkinson’s disease in mice by attenuating oxidative stress, inflammation, and apoptotic cell death and improving nerve growth factor gene expression And in a rat epilepsy model, frankincense oil pretreatment prevented the surge in oxidative stress markers and inflammatory molecules that normally follows severe seizures.11Clinical Phytoscience. Effect of frankincense oil on the neurochemical changes induced in rat model of status epilepticus
None of these studies tested neuropathy directly, but they consistently show that frankincense compounds reduce the kind of oxidative and inflammatory damage that drives diabetic nerve injury. The logic connecting these findings to neuropathy is reasonable, even though the direct evidence is missing. A diabetes researcher looking at these results would say the rationale is solid enough to justify a clinical trial, not solid enough to recommend the supplement.
The Bioavailability Problem
Even if boswellic acids do everything the animal studies suggest, there is a practical hurdle: getting enough of them into your body in active form. Boswellic acids dissolve poorly in water, which limits how much you absorb from a standard oral supplement. Pharmaceutical researchers have been working on this problem with some success. One group developed a lipid-based formulation of Boswellia serrata that achieved roughly two and a half times better absorption in rats compared with a standard commercial product.12Journal of medical pharmaceutical and allied sciences. Lipid based approach for bioavailability enhancement of boswellia serrata Another team engineered a peptide-based delivery system designed to shuttle AKBA across the blood-brain barrier, which is relevant for central neuropathic pain but far from commercially available.13Chemical Engineering Journal. Brain-targeted delivery of Acetyl-11-Keto-β-Boswellic acid with enhanced anti-inflammatory efficacy via blood-brain barrier peptide shuttle PepH3
For the average consumer, this means that the frankincense supplement you buy off a shelf may deliver much less active compound than the doses used in the animal studies that showed results. Some supplement manufacturers use proprietary extraction processes or pair boswellic acids with fats to improve absorption, but the quality and transparency of these products varies wildly. Without standardized dosing and formulation, it is hard to know whether a given product delivers a meaningful amount of AKBA to your tissues.
Not All Frankincense Is Created Equal
Adding to the uncertainty, the species of Boswellia tree matters a great deal. A direct chemical comparison of the two most commonly sold species found that Boswellia sacra contained about ten times more AKBA than Boswellia serrata.14PubMed Central. Quantitative Determination of 3-O-Acetyl-11-Keto-β-Boswellic Acid (AKBA) and Other Boswellic Acids in Boswellia sacra Flueck (syn. B. carteri Birdw) and Boswellia serrata Roxb That is not a small difference. If the dose of AKBA matters for therapeutic effect, and the animal data strongly suggest it does, then a product derived from B. serrata could have a fraction of the potency of one derived from B. sacra, even if both are labeled simply as “frankincense” or “boswellia extract.”
Most supplements sold in North America and Europe use B. serrata, which has been more widely studied in clinical contexts like osteoarthritis and inflammatory bowel disease. B. sacra is more common in traditional Arabian and East African medicine. Supplement labels do not always specify the species, and even when they do, AKBA content depends on extraction methods, growing conditions, and resin quality. If you are evaluating a frankincense product, look for one that lists a standardized percentage of boswellic acids or AKBA on the label. Products that just say “frankincense extract” without specifying active compound content could contain almost anything.
Why Frankincense and Myrrh Keep Appearing Together
You may have noticed that the strongest neuropathic pain studies used frankincense combined with myrrh, not frankincense alone. This pairing is not arbitrary. In traditional Chinese medicine, the two resins have been prescribed together for pain for centuries, and modern research suggests the combination produces stronger pain relief than either resin alone. The mouse study mentioned earlier specifically examined this pairing and found that the combined water extract reduced pain behavior through a mechanism involving the TRPV1 receptor, which is a major player in how you perceive burning and stinging pain.2PubMed Central. A Combined Water Extract of Frankincense and Myrrh Alleviates Neuropathic Pain in Mice via Modulation of TRPV1
The implication is that if frankincense does eventually prove useful for neuropathy in humans, it may work best as part of a multi-ingredient preparation rather than as a standalone supplement. This complicates research because combination products make it harder to isolate which ingredient is responsible for the benefit, and regulatory agencies tend to require evidence for each active ingredient separately. It also complicates consumer choices, since most frankincense supplements are sold on their own.
The Gap Between Animal Evidence and Human Proof
A review of essential oils for neuropathic pain noted that the literature is largely made up of preclinical animal models and a few experimental studies, some of which were poorly designed and did not clearly isolate the effects of the essential oil treatment.15PubMed Central. Essential Oils and Neuropathic Pain That assessment applies squarely to frankincense. The animal data is mechanistically rich and consistent across multiple labs and models, which is more than many herbal remedies can claim. But neuropathy research has a long history of compounds that look extraordinary in rodents and fail in human trials. Rodent nerves regenerate faster and more completely than human nerves. Surgically crushing a nerve is a very different injury from the gradual metabolic nerve death that happens in diabetes or chemotherapy. And the doses used in animal studies, when scaled to human body weight and metabolism, often turn out to be impractical or unsafe.
There are human trials of Boswellia serrata for other conditions, most notably osteoarthritis and inflammatory bowel disease, where it has shown modest but real anti-inflammatory benefits. Those trials at least confirm that boswellic acids are well-tolerated in humans and produce some measurable anti-inflammatory effect at oral doses. But pain reduction in an arthritic knee is a different question from nerve regeneration in the feet of someone with diabetic neuropathy. The mechanisms overlap, but the targets are not the same.
Practical Considerations If You Are Thinking About Trying It
If you have neuropathy and are considering frankincense, a few things are worth keeping in mind. First, frankincense supplements are not a replacement for the treatments with established evidence for neuropathic pain. Gabapentin, pregabalin, duloxetine, and certain tricyclic antidepressants have all been tested in large human trials for neuropathy and, while imperfect, have measurable benefits for many people. Frankincense has not cleared that bar yet.
Second, Boswellia supplements are generally well-tolerated at commonly sold doses, with gastrointestinal discomfort being the most frequently reported side effect. However, if you are on medications that are processed by certain liver enzymes, particularly CYP3A4 or CYP2C9, there is at least a theoretical concern about interactions, since boswellic acids have been studied for their potential to inhibit those enzymes. If you take blood thinners, antiepileptic drugs, or certain statins, mention any Boswellia supplement to your doctor or pharmacist.
Third, the dose and formulation matter enormously. A product with standardized AKBA content from a reputable manufacturer is likely to be more consistent than raw resin or unstandardized extract. Taking it with a fatty meal or choosing a lipid-based formulation may improve absorption. But even with optimal formulation, you are essentially experimenting on yourself with a product that has strong biological plausibility and zero direct human evidence for your condition.
Essential Oil Versus Oral Supplement
Frankincense is sold both as an oral supplement (usually standardized resin extract in capsules) and as an essential oil intended for topical use or aromatherapy. These are different products with different chemistry. Essential oils are produced by steam distillation and contain primarily volatile terpenes, while the boswellic acids responsible for the anti-inflammatory and nerve-repair effects in the research are non-volatile and remain in the resin after distillation. In other words, frankincense essential oil may smell nice and have some mild topical effects, but it contains little to none of the AKBA that drives the results in the studies described here.
People sometimes apply frankincense essential oil to their feet or hands for neuropathy symptoms, and some report temporary relief. Whether that relief comes from the oil’s minor active compounds, the act of massage itself, the warming or cooling sensation, or a placebo response is unclear. Massage alone has some evidence for reducing neuropathic pain symptoms temporarily. If you find that applying frankincense oil feels good, there is little risk in continuing, but do not confuse that experience with the pharmacological activity described in the research literature. The two products are not interchangeable.
Where the Research Needs To Go
The field has a clear road map, even if no one has driven it yet. A small pilot trial in people with diabetic peripheral neuropathy, using a standardized Boswellia extract with known AKBA content, measuring both pain outcomes and nerve conduction, would be a logical first step. Such a trial would be relatively inexpensive and low-risk given the established safety profile of Boswellia in humans. The frankincense-myrrh combination also deserves testing in a human neuropathy population, since the animal data for the pairing is actually stronger than for frankincense alone.
Until that work gets done, frankincense sits in a frustrating middle ground: too well-supported mechanistically to dismiss, but too far from clinical proof to recommend. For people living with neuropathic pain who have exhausted standard options, that ambiguity can feel especially maddening. The honest answer is that the biology is genuinely encouraging, the animal results are consistent, and the human evidence is simply absent. That gap may close in the coming years, but it has not closed yet.